Tests semaglutide during clot removal in adults with acute ischemic stroke
Tests semaglutide or saline placebo during clot removal in adults with stroke.
Key facts
- Who runs it
- RenJi Hospital
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 436 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 31 Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Semaglutide 0.5 mg
- Normal Saline
- Record updated
- 22 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having a stroke caused by a blocked brain artery, who are scheduled for a procedure to remove the clot (endovascular thrombectomy).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke diagnosed within 24 hours after onset, with endovascular thrombectomy planned. Before the stroke, the modified Rankin Scale (mRS) score was 1 or lower.
Main reasons for not taking part
- Bleeding in the brain on imaging before surgery, or within the 3 months before
- Reasons that make endovascular thrombectomy unsafe
- A recent earlier ischemic stroke
- Fasting blood glucose below 3.9 mmol/L (70 mg/dL)
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Clinical or imaging diagnosis of acute ischemic stroke within 24 hours after onset
- Scheduled for endovascular thrombectomy
- Age ≥18 years
- Pre-stroke modified Rankin Scale (mRS) score ≤1
- Informed consent voluntarily signed by the patient or legal representative
Who cannot take part
- Preoperative imaging diagnosis of intracranial hemorrhage, or history of intracranial hemorrhage within 3 months prior to surgery
- Recent history of ischemic stroke
- Severe organic heart disease or severe arrhythmia
- Contraindications to semaglutide or allergy to semaglutide
- Fasting blood glucose <3.9 mmol/L
- Contraindications for endovascular thrombectomy
- ASA classification of IV-V
- Pregnant or lactating women
Where in China
- Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Peiying Li MD，Ph.DNo longer taking part
About the trial
What the trial wants to find out
The trial will be a randomized, double-blind, controlled, single-center trial. The purpose of this trial is to determine the efficacy and safety of semaglutide in improving neurological outcomes after endovascular thrombectomy for acute ischemic stroke. The patients in the treatment group will receive a subcutaneous injection of 0.5 mg semaglutide into the abdomen during endovascular thrombectomy. The patients in the control group will receive a similar-looking placebo. Patients will be randomized to the treatment or control group by the pharmacy, eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients, further minimizing the bias.
The 2 groups in the trial
- semaglutide groupTreatment being tested
The patients will receive a subcutaneous injection of 0.5 mg semaglutide into the abdomen during endovascular thrombectomy
Treatment: Semaglutide 0.5 mg
- placebo groupPlacebo, for comparison
The patients in the control group will receive a similar-looking Normal Saline
Treatment: Normal Saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
- Plain-language title
- Tests semaglutide during clot removal in adults with acute ischemic strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 June 2025